## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.27 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates). Caution: declining volume (43% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($452.94)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. HCA Healthcare, Inc. 4th Quarter 2025 Earnings Conference Call**
- Source: Business Wire | 20251230T210212 | Neutral | Relevance: 100%
- HCA Healthcare, Inc. (NYSE: HCA) has announced its 4th Quarter 2025 Earnings Call will take place on Tuesday, January 27, 2026, at 9:00 AM Central (10:00 AM Eastern). The live audio webcast will be available on the company's investor relations website, with an archived version accessible afterward. Frank Morgan is the primary contact for investor relations regarding this event.

**2. Fort Washington Investment Advisors Inc. OH Trims Position in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251230T121024 | Somewhat-Bullish | Relevance: 100%
- Fort Washington Investment Advisors Inc. OH has reduced its stake in HCA Healthcare, Inc. by 16.1% in the third quarter, now holding 232,710 shares valued at approximately $99.18 million. Despite this reduction, HCA Healthcare reported strong Q3 earnings, beating analyst estimates for both EPS and revenue, and has a "Moderate Buy" consensus rating from analysts with an average price target of $479. The company also announced a quarterly dividend of $0.72 per share, and institutional ownership remains high at 62.73%.

**3. HCA Healthcare, Inc. $HCA Shares Sold by Diversified Trust Co**
- Source: MarketBeat | 20251230T101424 | Bullish | Relevance: 100%
- Diversified Trust Co significantly reduced its stake in HCA Healthcare (NYSE:HCA) by 51.4% in the third quarter, while other institutional investors made various adjustments. HCA Healthcare reported strong Q3 earnings, surpassing analyst expectations with $6.96 EPS and $19.16 billion in revenue, and provided optimistic FY2025 guidance. Analysts maintain a "Moderate Buy" rating for the stock, with an average price target of $479.

**4. Ethic Inc. Purchases 6,966 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251230T093411 | Bullish | Relevance: 100%
- Ethic Inc. significantly increased its stake in HCA Healthcare by 72.8% in Q3, purchasing 6,966 additional shares to bring its total holdings to 16,529 shares worth approximately $7.045 million. HCA Healthcare exceeded Q3 earnings estimates with EPS of $6.96 and revenue of $19.16 billion and raised its FY2025 guidance. The stock currently has a "Moderate Buy" rating from analysts with an average target price of $479.00.

**5. 5 financial metrics health system leaders are targeting next year**
- Source: Modern Healthcare | 20251229T050000 | Neutral | Relevance: 100%
- This article highlights five key financial metrics that health system leaders, including those at HCA and CommonSpirit, are focusing on for the upcoming year. It identifies these metrics as crucial for navigating the financial landscape of the healthcare industry. The article is authored by Alex Kacik and was published on December 29, 2025.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $520 | $505 | +3% |
| 2025-12-15 | Morgan Stanley | $425 | $425 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Outperform |
| 2025-12-15 | Morgan Stanley | down | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.27 suggests fair value with growth premium. Forward P/E 15.9x stretched relative to 7% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $110.7B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.27 |
| Forward P/E | 15.9 |
| Current P/E | 17.1 |
| YoY Growth | 7.3% |
| EPS Direction | RISING |

### Technicals

MRS_20 strengthening from -3.3% to -1.1% (+2.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.3%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.18x) but short-term weakness (below SMA20). MACD histogram bearish (-1.31), momentum weakening. RSI neutral at 48. Volume at 43% of 20MA suggests lack of conviction. OFD pattern: +DLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.15% (CS: 29) | Neutral |
| RSI_14 | 47.5 | Neutral |
| MACD Histogram | -1.31 | Bearish |
| vs SMA20 | 0.989x | Below |
| vs SMA50 | 0.997x | Below |
| vs SMA200 | 1.182x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $473.50
- **Stop Loss:** $452.94 (4.3% risk)
- **Target:** $514.62 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 64
- **Position Value:** $30,304.00
- **Portfolio %:** 30.30%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*